Case Based Roundtable Logo

Case-Based Roundtables on TargetedOnc.com are collaborative, small-group discussions about case-based clinical profiles and engaging peer-dialogue led by an expert physician. These resources offer practicing oncologists and hematologists insight on relevant data, treatment strategies, and varying professional opinions.

Latest Articles

Desai and Participants Differentiate BPDCN From Other Diagnoses
Desai and Participants Differentiate BPDCN From Other Diagnoses
July 25, 2024
During a Case-Based Roundtable® event, Pinkal Desai, MD, MPH, discusses the presentation of blastic plasmacytoid dendritic cell neoplasm vs other diseases in a patient case.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24, 2024
During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22, 2024
During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16, 2024
During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma
Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma
July 15, 2024
During a Case-Based Roundtable® event, Adam D. Cohen, MD, discussed triplet vs quadruplet options for a patient with transplant eligible multiple myeloma and NCCN recommendations in the first article of a 2-part series.
Dual ICI Considered for a Patient With NSCLC and Low PD-L1
Dual ICI Considered for a Patient With NSCLC and Low PD-L1
July 11, 2024
During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, discusses the use of immunotherapy combinations based on patients PD-L1 expression in the first article of a 2-part series.
Newer JAK Inhibitors Aid in Cytopenia Management for High-Risk Myelofibrosis
Newer JAK Inhibitors Aid in Cytopenia Management for High-Risk Myelofibrosis
July 10, 2024
During a Case-Based Roundtable® event, Kristen Pettit, MD, discussed the use of pacritinib and momelotinib in cytopenic myelofibrosis in the second article of a 2-part series.
COMMANDS Trial Shows Positive Result in MDS Despite Pandemic
COMMANDS Trial Shows Positive Result in MDS Despite Pandemic
July 09, 2024
During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 08, 2024
During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Patient Selection Factors for Earlier Use of CAR T-Cell Therapy
Patient Selection Factors for Earlier Use of CAR T-Cell Therapy
July 02, 2024
Binod Dhakal, MD, MS, discusses selecting patients for chimeric antigen receptor T-cell therapy by considering each patient’s condition and logistics.
A Deep Dive Into the FDA Approval of Imetelstat in Lower-Risk MDS
A Deep Dive Into the FDA Approval of Imetelstat in Lower-Risk MDS
July 01, 2024
Mikkael A. Sekeres MD, MS, further discussed the approval of imetelstat for the treatment of patients with low- to intermediate-1 risk myelodysplastic syndromes.
Ide-cel Shows Efficacy Earlier in R/R Multiple Myeloma Despite Crossover
Ide-cel Shows Efficacy Earlier in R/R Multiple Myeloma Despite Crossover
June 28, 2024
During a Case-Based Roundtable® event, Surbhi Sidana, MD, discussed the KarMMa-3 trial of earlier-line CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS
Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS
June 27, 2024
During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.
Patient Considerations for Using Dual Immunotherapy for RCC
Patient Considerations for Using Dual Immunotherapy for RCC
June 26, 2024
During a Case-Based Roundtable® event, Nizar M. Tannir, MD, discussed the importance of site of metastasis and other factors in the use of nivolumab plus ipilimumab in renal cell carcinoma in the first article of a 2-part series.
Selinexor Triplet Reviewed as Second-Line Option in Multiple Myeloma
Selinexor Triplet Reviewed as Second-Line Option in Multiple Myeloma
June 24, 2024
During a Case-Based Roundtable® event, Jack Khouri, MD, looked at selinexor trial data for a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
View a specific disease type